Migraine

>

Latest News

 Implantable Neuromodulation Device Shows Sustained Benefit in Chronic Migraine at 12 Months
Implantable Neuromodulation Device Shows Sustained Benefit in Chronic Migraine at 12 Months

September 16th 2025

The investigational ShiraTronics Migraine Therapy System delivered an average of 9.6 migraine-free days per month, reduced rescue medication use, and improved QOL.

Fremanezumab Label Expanded for Treatment of Episodic Migraine in Children Aged 6 to 17 Years
Fremanezumab Label Expanded for Treatment of Episodic Migraine in Children Aged 6 to 17 Years

August 6th 2025

 Atogepant Superior to Topiramate for Migraine Prevention in Phase 3 Head-to-Head TEMPLE Study / image credit ©mopic/shutterstock.com
Atogepant Superior to Topiramate for Migraine Prevention in Phase 3 Head-to-Head TEMPLE Study

June 18th 2025

Fremanezumab Demonstrates Dual Benefits in Adults with Migraine and Depression
Fremanezumab Demonstrates Dual Benefits in Adults with Migraine and Depression

May 6th 2025

FDA Approves Atzumi (Dihydroergotamine) Nasal Powder for Acute Treatment of Migraine / image credit ©Waldenmarus/stock.adobe.com
FDA Approves STS101 (Dihydroergotamine) Nasal Powder for Acute Treatment of Migraine

May 1st 2025

More News

© 2025 MJH Life Sciences

All rights reserved.